Assessment of Immunomodulatory Activities and in vitro Toxicity of New Quinolone 7-ethyl 9-ethyl-6-oxo-6,9-dihydro[1,2,5]selenadiazolo[3,4-h]quinoline-7-carboxylate

References

• Abdel-Aziz M, Park SE, Abuo-Rahma Gel D, et al. 2013. Novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids: synthesis, physicochemical properties, anticancer and topoisomerase I and II inhibitory activity. Eur J Med Chem, 69, 427–438.
   PubMed Web of Science ®Google Scholar
• Azema J, Guidetti B, Dewelle J, Le Calve B, et al. 2009. 7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents. Bioorg Med Chem, 17, 5396–5407.
   PubMed Web of Science ®Google Scholar
• Barbierikova Z, Bella M, Kucerak J, et al. 2011a. Photoinduced superoxide radical anion and singlet oxygen generation in the presence of novel selenadiazoloquinolones (an EPR Study). Photochem Photobiol, 87, 32–44.
   PubMed Web of Science ®Google Scholar
• Barbierikova Z, Bella M, Lietava J, et al. 2011b. Spectroscopic characterization and photoinduced processes of 4-oxoquinoline derivatives. J Photoch Photobio A, 224, 123–134.
   Web of Science ®Google Scholar
• Barbieriková Z, Bella M, Sekeráková Ľ, et al. 2013. Spectroscopic characterization, photoinduced processes and cytotoxic properties of substituted N-ethyl selenadiazoloquinolones. J Phys Organic Chem, 26, 565–574.
   Web of Science ®Google Scholar
• Barrett AJ, Le Blanc K. 2010. Immunotherapy prospects for acute myeloid leukaemia. Clin Exp Immunol 161, 223–232.
   PubMed Web of Science ®Google Scholar
• Bella M, Milata V. 2014. Synthesis of 9-ethyl[1,2,5]selenadiazolo[3,4-h]quinolones by the application of modified Gould-Jacobs reaction to N-ethyl-2,1,3-benzoselenadiazol-4- amine. Arkivoc, 181–198.
   Google Scholar
• Blasi F, Tarsia P, Aliberti S, et al. 2006. Highlights on the appropriate use of fluoroquinolones in respiratory tract infections. Pulm Pharmacol Ther, 19(Suppl 1), 11–19.
   Google Scholar
• Cheng YY, Yang JS, Tsai SC, et al. 2012. The newly synthesized 2-(3-hydroxy-5-methoxyphenyl)-6,7-methylenedioxyquinolin-4-one triggers cell apoptosis through induction of oxidative stress and upregulation of the p38 MAPK signaling pathway in HL-60 human leukemia cells. Oncol Rep, 28, 1482–1490.
   PubMed Web of Science ®Google Scholar
• Chou LC, Yang JS, Huang LJ, et al. 2009. The synthesized 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one (CHM-1) promoted G2/M arrest through inhibition of CDK1 and induced apoptosis through the mitochondrial-dependent pathway in CT-26 murine colorectal adenocarcinoma cells. J Gastroenterol, 44, 1055–1063.
   PubMed Web of Science ®Google Scholar
• Chung DT, Tsai CY, Chen SJ, et al. 2010. Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Antimicrob Agents Chemother, 54, 411–417.
   PubMed Web of Science ®Google Scholar
• Costello RT. 1993. Therapeutic use of granulocyte-macrophage colony-stimulating factor (GM-CSF). A review of recent experience. Acta Oncol, 32, 403–408.
   PubMed Web of Science ®Google Scholar
• Crane JK, Mongiardo KM. 2014. Pro-inflammatory effects of uric acid in the gastrointestinal tract. Immunol Invest, (43), 255–266.
   PubMed Web of Science ®Google Scholar
• Dalhoff A. 2005. Immunomodulatory activities of fluoroquinolones. Infection, (33), 55–70.
   PubMed Web of Science ®Google Scholar
• Dalhoff A, Shalit I. 2003. Immunomodulatory effects of quinolones. Lancet Infectious Dis, 3, 359–371.
   PubMed Web of Science ®Google Scholar
• Drygin D, Siddiqui-Jain A, O’Brien S, et al. 2009. Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer Res, 69, 7653–7661.
   PubMed Web of Science ®Google Scholar
• Du P, Viswanathan UM, Khairan K, et al. 2014. Synthesis of amphiphilic, chalcogen-based redox modulators with in vitro cytotoxic activity against cancer cells, macrophages and microbes. Medchemcomm, 5, 25–31.
   Web of Science ®Google Scholar
• Eucker J, Zang C, Zhou Y, et al. 2014. TKI258, a multi-tyrosine kinase inhibitor is efficacious against human infant/childhood lymphoblastic leukemia in vitro. Anticancer Res, 34, 4899–4907.
   PubMed Web of Science ®Google Scholar
• Fallon J, Tighe R, Kradjian G, et al. 2014. The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget, 5, 1869–1884.
   PubMed Web of Science ®Google Scholar
• Farzin H, Toroghi R, Haghparast A. 2016. Up-Regulation of pro-inflammatory cytokines and chemokine production in avian influenza H9N2 virus-infected human lung epithelial cell line (A549). Immunol Inves, 45, 116–129.
   PubMed Web of Science ®Google Scholar
• George S, Pili R. 2013. Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer. Curr Oncol Rep, 15, 65–68.
   PubMed Web of Science ®Google Scholar
• Gruia MI, Negoita V, Vasilescu M, et al. 2015. Biochemical action of new complexes of ruthenium with quinolones as potential antitumor agents. Anticancer Res, 35, 3371–3378.
   PubMed Web of Science ®Google Scholar
• Hamilton-Miller JM. 2001. Immunopharmacology of antibiotics: direct and indirect immunomodulation of defence mechanisms. J Chemother 13, 107–111.
   PubMed Web of Science ®Google Scholar
• Hasinoff BB, Wu X, Nitiss JL, et al. 2012. The anticancer multikinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Biochem Pharmacol, 84, 1617–1626.
   PubMed Web of Science ®Google Scholar
• Hotinski AK, Lewis ID, Ross DM. 2015. Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia. Expert Opin Pharmacother, 16, 1395–1402.
   PubMed Web of Science ®Google Scholar
• Huang L, Hsieh M, Teng C, et al. 1998. Synthesis and antiplatelet activity of phenyl quinolones. Bioorg Med Chem, 6, 1657–1662.
   PubMed Web of Science ®Google Scholar
• Huang SM, Yang JS, Tsai SC, et al. 2011. The novel synthesized 2-(3-(methylamino)phenyl)-6-(pyrrolidin-1-yl)quinolin-4-one (Smh-3) compound induces G2/M phase arrest and mitochondrial-dependent apoptotic cell death through inhibition of CDK1 and AKT activity in HL-60 human leukemia cells. Int J Oncol, 38, 1357–1364.
   PubMed Web of Science ®Google Scholar
• Jantová S, Cipak L, Letašiová S. 2007. Berberine induces apoptosis through a mitochondrial/caspase pathway in human promonocytic U937 cells. Toxicol In Vitro, 21, 25–31.
   PubMed Web of Science ®Google Scholar
• Jantová S, Konariková K, Letašiová S, et al. 2011. Photochemical and phototoxic properties of ethyl 1,4-dihydro-8-nitro-4-oxoquinoline-3-carboxylate, a new quinoline derivative. J Photochem Photobiol, B 102, 77–91.
   PubMed Web of Science ®Google Scholar
• Jantová S, Letašiová S, Koňariková K, et al. 2010. Effect of new synthetically prepared quinolone ethyl-1,4-dihydro-8-nitro-4-oxoquinoline-3-carboxylate on human leukemia cell line HL-60 without/with presence of UVA irradiation. Acta Chimica Slovaca, 3, 51–72.
   Google Scholar
• Jantová S, Mrvová N, Hudec R, et al. 2016. Pro-apoptotic effect of new quinolone 7-ethyl-9-ethyl-6-oxo-6,9-dihydro[1,2,5]selenadiazolo[3,4-h]quinoline-7-carboxylate on cervical cancer cell line HeLa alone/with UVA irradiation. Toxicol In Vitro, 33, 35–44.
   PubMed Web of Science ®Google Scholar
• Kakadiya R, Wu YC, Dong H, et al. 2011. Novel 2-substituted quinolin-4-yl-benzenesulfonate derivatives: synthesis, antiproliferative activity, and inhibition of cellular tubulin polymerization. ChemMedChem, 6, 1119–1129.
   PubMed Web of Science ®Google Scholar
• Khader SA, Gopal R. 2010. IL-17 in protective immunity to intracellular pathogens. Virulence, 1, 423–427.
   PubMed Web of Science ®Google Scholar
• Khan AA, Slifer TR, Remington JS. 1998. Effect of trovafloxacin on production of cytokines by human monocytes. Antimicrob Agents Chemother, 42, 1713–1717.
   PubMed Web of Science ®Google Scholar
• Koziel R, Szczepanowska J, Magalska A, et al. 2010. Ciprofloxacin inhibits proliferation and promotes generation of aneuploidy in Jurkat cells. J Physiol Pharmacol, 61, 233–239.
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, Vantwout JW. 1994. Cytokines in the treatment of fungal-infections. Biotherapy, 7, 195–210.
   PubMedGoogle Scholar
• Kuroki M, Miyamoto S, Morisaki T, et al. 2012. Biological response modifiers used in cancer biotherapy. Anticancer Res, 32, 2229–2233.
   PubMed Web of Science ®Google Scholar
• Kuwahara K, Kitazawa T, Kitagaki H, et al. 2005. Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. J Dermatol Sci, 38, 47–55.
   PubMed Web of Science ®Google Scholar
• Lai TY, Yang JS, Wu PP, et al. 2010. The quinolone derivative CHM-1 inhibits murine WEHI-3 leukemia in BALB/c mice in vivo. Leuk Lymphoma, 51, 2098–2102.
   PubMed Web of Science ®Google Scholar
• Landskron G, De la Fuente M, Thuwajit P, et al. 2014. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res, 2014, 149185.
   PubMed Web of Science ®Google Scholar
• Leibovitz E. 2006. The use of fluoroquinolones in children. Curr Opin Pediatr 18, 64–70.
   PubMed Web of Science ®Google Scholar
• Letašiová S, Jantová S, Čipák L, Múčková M. 2006. Berberine-antiproliferative activity in vitro and induction of apoptosis/necrosis of the U937 and B16 cells. Cancer Lett, 239, 254–262.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Pierotti MA. 2008. Cancer and inflammation: a complex relationship. Cancer Lett, 267, 180–181.
   PubMed Web of Science ®Google Scholar
• Meyer E, Schwab F, Gastmeier P, et al. 2007. Antifungal use in intensive care units. J Antimicrob Chemother, 60, 619–624.
   PubMed Web of Science ®Google Scholar
• Mihich E. 2000. On the immunomodulating effects of anti-cancer drugs and their therapeutic exploitation. Jpn J Clin Oncol, 30, 469–471.
   PubMed Web of Science ®Google Scholar
• Mocellin S, Marincola FM, Young HA. 2005. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol, 78, 1043–1051.
   PubMed Web of Science ®Google Scholar
• Ono Y, Ohmoto Y, Ono K, et al. 2000. Effect of grepafloxacin on cytokine production in vitro. J Antimicrob Chemother, 46, 91–94.
   PubMed Web of Science ®Google Scholar
• Oriel JD. 1989. Use of quinolones in chlamydial infection. Rev Infect Dis, 11(Suppl 5), S1273–S1276.
   Google Scholar
• Repicky A, Jantova S, Cipak L. 2009. Apoptosis induced by 2-acetyl-3-(6-methoxybenzothiazo)-2-yl-amino-acrylonitrile in human leukemia cells involves ROSmitochondrial mediated death signaling and activation of p38 MAPK. Cancer Lett, 277, 55–63.
   PubMed Web of Science ®Google Scholar
• Riesbeck K. 2002. Immunomodulating activity of quinolones: review. J Chemother 14, 3–12.
   PubMed Web of Science ®Google Scholar
• Riesbeck K, Forsgren A. 1994. Increased interleukin 2 transcription in murine lymphocytes by ciprofloxacin. Immunopharmacology, 27, 155–164.
   PubMed Web of Science ®Google Scholar
• Santos Fda C, Abreu P, Castro HC, et al. 2009. Synthesis, antiviral activity and molecular modeling of oxoquinoline derivatives. Bioorg Med Chem, 17, 5476–5481.
   PubMed Web of Science ®Google Scholar
• Sayers TJ. 2011. Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother, 60, 1173–1180.
   PubMed Web of Science ®Google Scholar
• Scatena CD, Kumer JL, Arbitrario JP, et al. 2010. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo. Cancer Chemother Pharmacol, 66, 881–888.
   PubMed Web of Science ®Google Scholar
• Shaikh PZ. 2011. Cytokines & their physiologic and pharmacologic functions in inflammation: A review. Int J Pharmacy Life Sci, 2, 1247–1263.
   Google Scholar
• Shalit I. 1991. Immunological aspects of new quinolones. Eur J Clin Microbiol Infect Dis, 10, 262–266.
   PubMed Web of Science ®Google Scholar
• Sharma PC, Jain A, Jain S. 2009. Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects. Acta Pol Pharm, 66, 587–604.
   PubMed Web of Science ®Google Scholar
• Sokolova GB, Kunichan AD, Lazareva Ia V. 2009. [Levofloxacin (Tavanic) in complex therapy of tuberculosis]. Antibiot Khimioter, 54, 31–37.
   PubMedGoogle Scholar
• Stieglitz E, Ward AF, Gerbing RB, et al. 2015. Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer, 62, 629–636.
   Google Scholar
• Tawfik AF, Shoeb HA, Bishop SJ, et al. 1990. Influence of new quinolones on normal immune capabilities. J Chemother, 2, 300–305.
   PubMed Web of Science ®Google Scholar
• Vickers IE, Smikle MF. 2006. The immunomodulatory effect of antibiotics on the secretion of tumour necrosis factor alpha by peripheral blood mononuclear cells in response to Stenotrophomonas maltophilia stimulation. West Indian Med J, 55, 138–141.
   PubMed Web of Science ®Google Scholar
• Vinayaka AC, Sadashiva MP, Wu X, et al. 2014. Facile synthesis of antimalarial 1,2-disubstituted 4-quinolones from 1,3-bisarylmonothio-1,3-diketones. Org Biomol Chem, 12, 8555–8561.
   PubMed Web of Science ®Google Scholar
• Williams AC, Galley HF, Watt AM, Webster NR. 2005. Differential effects of three antibiotics on T helper cell cytokine expression. J Antimicrob Chemother, 56, 502–506.
   PubMed Web of Science ®Google Scholar
• Winter E, Chiaradia LD, Silva AH, et al. 2014. Involvement of extrinsic and intrinsic apoptotic pathways together with endoplasmic reticulum stress in cell death induced by naphthylchalcones in a leukemic cell line: advantages of multi-target action. Toxicol In Vitro, 28, 769–777.
   PubMed Web of Science ®Google Scholar
• Xia Y, Yang ZY, Xia P, et al. 2001. Antitumor Agents. 211. Fluorinated 2-phenyl-4-quinolone derivatives as antimitotic antitumor agents. J Med Chem, 44, 3932–3936.
   PubMed Web of Science ®Google Scholar
• Xue X, Lai KT, Huang JF, et al. 2006. Anti-inflammatory activity in vitro and in vivo of the protein farnesyltransferase inhibitor tipifarnib. J Pharmacol Exp Ther, 317, 53–60.
   PubMed Web of Science ®Google Scholar
• Yanamandra N, Buzzeo RW, Gabriel M, et al. 2011. Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels. J Pharmacol Exp Ther, 337, 636–643.
   PubMed Web of Science ®Google Scholar
• Yang JS, Park CH, Lee C, et al. 2014. Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents. Eur J Med Chem, 85, 399–407.
   PubMed Web of Science ®Google Scholar
• You QD, Li ZY, Huang CH, et al. 2009. Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification. J Med Chem, 52, 5649–5661.
   PubMed Web of Science ®Google Scholar
• Zhang L, Freeman LE, Nakamura J, et al. 2010. Formaldehyde and leukemia: epidemiology, potential mechanisms, and implications for risk assessment. Environ Mol Mutagen, 51, 181–191.
   PubMed Web of Science ®Google Scholar